This study aimed to assess the cost-effectiveness of TLE-CHM as an initial treatment for HER2-negative advanced G/GEJ adenocarcinoma from the perspective of the Chinese healthcare system. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.